Background: The mutation of TANK-binding kinase 1 (TBK1) gene has been re-
| INTRODUCTION
Frontotemporal dementia (FTD) is a progressive neurodegenerative syndrome with the clinical manifestations of executive dysfunction, language deficits, and behavior as well as personality changes (Perry & Miller, 2013) . It was the second common in young-onset dementia, accounting for 20% dementia in 45-64 age-group (Mercy, Hodges, Dawson, Barker, & Brayne, 2008) . Its clinical subtypes include behavioral variant FTD (bvFTD) and two primary progressive aphasias: nonfluent aphasia and semantic dementia. Extrapyramidal symptoms and/or amyotrophic lateral sclerosis (ALS) could also be presented in FTD patients (Fujioka & Wszolek, 2011) .
Frontotemporal dementia is a syndrome of genetic heterogeneity. Since MAPT was first identified as the causative gene of FTD in 1998, an increasing number of pathogenic genes have been reported associated with FTD including GRN, C9orf72, VCP, SQSTM1, CHMP2B, TBK1, OPTN, TARDBP, CHCHD10, UBQLN2, and DCTN1 (Pottier, Ravenscroft, Sanchez-Contreras, & Rademakers, 2016) . Most of them were also the causative genes of ALS except for GRN (Mackenzie & Neumann, 2016; Renton et al., 2011; Van Mossevelde, van der Zee, Cruts, & Van Broeckhoven, 2017) . Besides, approximately 15% FTD patients develop clinical features of ALS (Lomen-Hoerth, Anderson, & Miller, 2002) and up to 15% ALS patients finally reach the criteria of FTD, ALS, and FTD are now considered as ALS-FTD spectrum, other than two separate diseases.
TBK1 (OMIM:604834) is the causative genes of FTD-ALS recognized recently based on a large-scale wholeexome sequencing study and the following variant analysis (Cirulli et al., 2015; Le Ber et al., 2015) . Up till now, more than 70 TBK1 variants have been reported in ALS, FTD, or FTD-ALS patients and most were Caucasian (Ahmad, Zhang, Casanova, & Sancho-Shimizu, 2016) . Its encoding protein, tumor necrosis factor receptor-associated factor NF-kB activator-binding kinase 1 (TBK1), was a serine/ threonine protein kinase involved in multiple cellular pathways. It has functions in neuroinflammation through NF-κB pathway and can interact with downstream proteins such as optineurin and p62, which are involved in selective autophagy degradation. In vitro functional assessments showed that mutations of TBK1 were associated with disruption of inflammation or autophagy pathways for the impairment of optineurin binding or IFN-β signaling inducement, respectively (Freischmidt et al., 2015) .
In this study, we reported a Chinese FTD patient carrying mutation of p.Ile334Thr in TBK1. This mutation was firstly reported by Shu et al. in a Chinese ALS patient with no symptoms of FTD (Shu et al., 2016) . We also performed the in vitro functional studies to investigate its potential pathogenesis.
| METHODS

| Ethical compliance
This research was approved by the Institutional Ethics Committee of Huashan Hospital Fudan University. The study was conducted after receiving written informed consent from the patient.
| Clinical materials
The patient came from central China. The clinical materials were collected. Blood biochemical analysis (serum creatine kinase, electrolytes, glucose, retinal and liver function, thyroxine, thyroid-stimulating hormone, and sedimentation rate) and examinations including cranial magnetic resonance imaging (MRI), positron emission computed tomography (PET/CT), electromyography plus nerve conduction velocity (EMG+NCV), electroencephalogram (EEG), and neuropsychological assessments were carried out.
The diagnosis of bvFTD was made according to the Rascovsky criteria (Rascovsky et al., 2011) .
| Genetic test
Genomic DNA was extracted from peripheral blood through a standard method (Qiagen, German). A panel containing over 4,000 known virulence genes was performed by target sequencing of the exons. In brief, all exons and their corresponding flanking regions of these genes were selected as target regions. Paired-end sequencing was performed on Illumina HiSeq X-ten platform. All variants different from the reference sequence were further screened by allele frequency <1% according to 1,000 Genomes Project (http://www.internationalgenome.org/data), Inhouse database, ESP6500 (evs.gs.washington.edu/EVS/), and ExAC (exac.broadinstitute.org). The synonymous variants were excluded. The phenotypes of the screened genes were compared with the clinical manifestations of the patient, and the inherited modes were considered to further exclude irrelevant genes. Then, the mutations left were confirmed by Sanger sequencing. The databases including Mutation Taster and MUpro were used to predict the pathogenicity of the variants.
The GenBank version was CM000674.1. The NCBI Reference Sequence of TBK1 gene in this study was NC_000012.11, with a transcript ID of ENST00000331710.5. The NCBI Reference Sequence of TBK1 mRNA was NM_013254.4, which encodes a protein of 729 amino acids (NP_037386.1). Interpretation of the variants was based on the American College of Medical Genetics and Genomics (ACMG) recommended standards (Richards et al., 2015) .
| In vitro functional studies
| Cell culture and transfection
Fibroblasts were obtained from this patient and healthy controls. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% FBS (Gibco, Carlsbad, CA, USA), nonessential amino acids (Gibco), sodium bicarbonate (Sigma-Aldrich, St. Louis, MO, USA), and 1% (vol/vol) penicillin/streptomycin/fungizone (Cellgro, Manassas, VA, USA) in an incubator at 37°C under 5% CO 2.
HEK293T cells were cultured in DMEM with 10% FBS in an incubator at 37°C under 5% CO 2 . For transient overexpression, cells were transfected with Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions.
| TBK1 and phosphorylated IRF3 protein analysis
Fibroblasts from both healthy control and the patient were washed twice with phosphate-buffered saline (PBS) and lysed in RIPA buffer with protease and phosphatase inhibitor cocktails on ice. Proteins were resolved by SDS-PAGE and transferred to a PVDF membrane (GE Healthcare, Little Chalfont, UK). After being blocked with 5% skim milk, the membrane was then incubated with primary antibodies overnight, followed by HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA). Detection was made with a West-Q Chemiluminescent Substrate Plus Kit (GenDEPOT, Barker, TX, USA).
| TBK1 quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated with RNA isoplus (Takara, Japan) from the fibroblast, and cDNA was synthesized via Toyobo cDNA kit (Toyobo, Japan). Power SYBR Green PCR Master Mix and primers were used to amplifying cDNA. The relative quantities (RQs) of TATA-binding protein (TBP) were calculated as internal control in the 2 −ΔΔC t method. The following primers were used in this study: TBK1, 5′-CGAGATGTGGTGGGTGGAATG-3′ and 5′-CACAGACTGTCCATCTTCCCC-3′; TBP, 5′-CCC ATGACTCCCATGACC-3′ and 5′-TTTACAACCAAGATT CACTGTGG-3′.
| Plasmids and constructs
N-terminally GFP-tagged wild-type human TBK1 cDNA was cloned into the pReceiver vector (GeneCopoeia, Rockville, MD, USA). The missense variants (c.1001T>C, p.Ile334Thr) were introduced into wild-type GFP-TBK1 using the EZchange™ site-directed mutagenesis kit (Enzynomics, Daejeon, Korea) according to the manufacturer's protocol. For expression in bacteria, OPTN cDNA fragments were amplified by PCR and subcloned into pGEX6P1 (GE Healthcare). All constructs were verified by Sanger sequencing.
| GST pull-down assay
Recombinant GST fusion protein GST-OPTN was produced in E. coli BL-21 cells. HEK293T cells were transfected with plasmids of wild-type human TBK1 and p.Ile334Thr TBK1 separately. Both cells were lysed in lysis buffer of GST Protein Interaction Pull-Down Kit (Thermo Scientific™, #21516). Following experiments were performed according to the manufacturer's protocol.
| Luciferase reporter assay
For luciferase reporter assays, HEK293T cells were cultured on 24-well plates and cotransfected with a plasmid encoding an IFN-β luciferase reporter (NanoLuc luciferase; 500 ng), pGL4.54 (firefly luciferase plasmid; 50 ng), and 1,000 ng of a plasmid-encoding GFP-tagged wild-type or p.Ile334Thr TBK1. Transfection was performed with Lipofectamine 2000 (Invitrogen). At 24 hr post-transfection, the cells were washed with PBS. The levels of luciferase activity (NanoLuc luciferase and firefly luciferase) were measured according to the manufacturer's protocol (Promega, Mannheim, Germany). Three independent experiments were performed using triplicate samples in each experiment.
| Antibodies
Anti-TBK1 (1:1,000; Thermo Fisher Scientific, Rockford, IL, PA5-17478), anti-IRF3 (1:1,000; Abcam, MA, #ab25950), anti-pIRF3 (Ser396) (1:500 Cell Signaling, MA, 4D4G, #4947), anti-OPTN(1:1,000, Proteintech, 108371-AP), and anti-β-actin (1:10,000; Sigma, #A5060) antibodies were used. The following secondary HRP-conjugated antibodies were used for immunoblotting: goat anti-mouse IgG (1:1,000; Santa Cruz, CA, #sc-2005) and goat anti-rabbit IgG (1:1,000; Santa Cruz, #sc-2004).
| RESULTS
| Clinical evaluation
The patient was a 38-year-old female who referred to Huashan Hospital after a one-year history of slowness in reaction, changes in personality, slow movement, and stiffness in her extremities under no predisposing cause. She has no past medical history. She had a suspicious family history as her father had "mental problem" and got lost in his thirties. During her last physical examination, two years from disease onset, the patient showed less cooperation, hyperactivity, and communication difficulties. She also showed stereotyped movement which was repeatedly rubbing her left thigh with her left hand several times and then touching her mouse or hair. Forced grasping was induced in her left hand. Her right hand presented stiffness of all fingers and could not perform fine operations. There was no muscle atrophy. Muscle strength and deep tendon reflexes were normal, while the muscle tone of her upper limbs was elevated with the right one more obvious. Bilateral Babinski signs, Hoffmann signs, and palmomental reflex were negative. The patient scored 12 in Neuropsychiatry Inventory Assessment, 39 in Dysexecutive Questionnaire, 33 in Frontal Behavioral Inventory, and 10.5 in Clinical Dementia Rating (sum of box), suggesting severe cognitive impairment particularly in executive dysfunction, attention deficit, and loss of empathy (Table 1) . Cranial MRI indicated bilateral frontotemporal atrophy ( Figure 1a ). Her PET-CT findings also suggested severe bilateral frontotemporal hypometabolism ( Figure  1b ). Both EMG and EEG were normal. She was diagnosed as bvFTD and donepezil, amantadine and clonidine were prescribed.
| Mutation analysis
The mean depth of target sequencing of the patient was 247.96X. The percentage of the target region with mean depth over 20X was 99.7%. According to the criteria mentioned above, only one heterozygous mutation of c.1001T>C in TBK1 was found, leading to a p.Ile334Thr change in exon 9 (Figure 2a) . The MAF of the variant TBK1 p.Ile334Thr (12:64878091 T/C) was about C = 2/102,266 in the total population. The variant was not detected in 200 Chinese seniors without medical history of neurological diseases from the community by Sanger sequencing. The evaluation by Mutation Taster (Schwarz, Cooper, Schuelke, & Seelow, 2014) and MUpro (Cheng, Randall, Sweredoski, & Baldi, 2005) suggested the variant be deleterious: Mutation Taster-Disease causing, with a score of 89; MUpro-Decrease stability, with a score of −1.85. Furthermore, according to the protein analysis on a website (http://www.cmbi.ru.nl/hope/), the mutant residue became smaller and less hydrophobic than the wild type, which might lead to a possible loss of interaction with other molecules on the surface of the protein (Figure 2b,c) . The wild-type residue was not conserved at this position (Figure 2d ).
| Expression and function analysis
Compared with control fibroblasts, the mRNA level of TBK1 in the fibroblasts with p.Ile334Thr variant was decreased by about 50% (Figure 3a) , and the same was found in the protein expression (Figure 3b,c) .
TBK1 is known to phosphorylate IRF3 and regulate its dimerization and nucleus translocation, which participate significantly in the activation of IFN pathway in inflammation. Thus, the protein level of phosphorylated IRF3 in the fibroblasts of p.Ile334Thr variant was also evaluated and found CCD2 domain of TBK1 phosphorylated its downstream binding protein optineurin. Phosphorylated optineurin then took part in the autophagy. It would be of interest to further test whether autophagy defects are observed in p.Ile334Thr mutant. Here, we examined the direct interactions between TBK1 and optineurin through GST pull-down assay. We transfected HEK293T cells with GFP-tagged wild-type or p.Ile334Thr form of TBK1. The whole cell lysates of HEK293T cell were subjected to GST pull-down assay with GST-OPTN. Immunoblotting showed that both wild-type and p.Ile334Thr TBK1 could bind with optineurin ( Figure  4b ), indicating normal function of TBK1 CCD2 domain.
According to ACMG guideline, the variant was classified as likely pathogenic (Richards et al., 2015) .
| DISCUSSION
In the present study, we described an early-adult onset patient of FTD, carrying a TBK1 mutation of p.Ile334Thr. The patient displayed severe behavior changes and cognitive impairment especially in executive functions but no evidence of ALS. Further experiments showed reduced transcription and expression level of TBK1 as well as decreased IFN-β signaling but normal binding ability with downstream autophagy receptor optineurin, indicating dysfunction of inflammatory pathway with this mutation.
The FTD-ALS causative gene TBK1 contributed to about 1.3% ALS, 3%-4% ALS-FTD, and <1% FTD with TDP-43 pathology (Nguyen, Van Broeckhoven, & van der Zee, 2018) , of whom great clinical heterogeneity was presented. Considering the TBK1 variants, clinical manifestations of reported mutations in FTD-ALS spectrum were listed (Table 2) . Among the patients with TBK1 mutations, over 50% patients were diagnosed as ALS, as well as 18% FTD, 14% FTD-ALS, and 1.3% AD. The age at onset varied from 26 to 86, with a disease course ranging from <1 year to more than 10 years, and approximately 18% patients died within 2 years. The most common initial symptoms included limb weakness, cognitive deficits, bulbar signs such as dysarthria and dysphagia. Interestingly, about half of the patients with TBK1 mutations were identified with cognitive impairment and one-thirds with bulbar symptoms. Intrafamilial and interfamilial heterogeneity were also seen in patients carrying the same mutants (Freischmidt et al., 2015) . The TBK1 p.Ile334Thr mutation was first reported in a sporadic (Shu et al., 2016) . However, in our case, the patient displayed bvFTD, suggesting this mutation may be obligated to FTD-ALS spectrum.
Although the Caucasian accounts for most of TBK1 mutants, mutations in TBK1 also accounted for sALS patients of Asian population. The frequency of pathogenic or potentially toxic variants of TBK1 in Korean and Japanese sALS patients was estimated to be 0.8% and 1.26% separately (Kim et al., 2017; Tohnai et al., 2018) . Besides, five missense variants of TBK1 have been reported in ALS patients of Chinese population so far, among which only the patient with p.Arg444X displayed FTD-ALS, while the others reported no cognitive dysfunction (Tsai et al., 2016) . In addition, one frameshift mutation (p.Leu339fs) of Chinese origin was also found in an Australian cohort study of ALS (Williams et al., 2015) . Taken together, although infrequent, TBK1 mutants can still be considered responsible for ALS-FTD spectrum in Chinese patients.
TBK1 encodes a multimeric kinase regulating multiple cellular pathways, especially inflammation and autophagy. It consists of 4 domains: a kinase domain (KD), an ubiquitin-like domain (ULD), a helical scaffold dimerization domain (SDD), and a C-terminal domain (Larabi et al., 2013) . TBK1 phosphorylates transcription factor IRF3 in the C-terminal regulatory domain, leading to its dimeration. Phosphorylated IRF3 then translocates to the nucleus, initiating the transcription of type I interferon genes. The ULD is a regulatory component of TBK1 which controls homodimerization, kinase activation, and interactions with other molecules in the IFN pathway (Li et al., 2012) . The p.Ile334Thr mutation locates in the ULD region. Via in vitro functional study, we found reduced expression level of TBK1 mRNA and protein, as well as disruption in the luciferase activity of IFN-β, the same as p.Arg357Gln variant which is also located in the ULD region (Freischmidt et al., 2015) . Our results implied that TBK1 p.Ile334Thr mutation disturbed TBK1 homodimerization and kinase activation, resulting in impairment of downstream neuroinflammatory pathways.
CCD2 mutations abrogated optineurin binding, which is necessary for selective autophagy, but not phosphorylation and activation of IRF3. TBK1 interacts with autophagy receptor proteins which can bind with ubiquitinated cargos and transport them into autophagosomes. In addition, TBK1 T A B L E 2 (Continued) also participates in the process of transferring autophagosomes into hydrolytic autophagolysosome, leading to the final degradation of autophagy receptors and their target cargo (Freischmidt et al., 2015) . In our work, p.Ile334Thr TBK1 seemed to have normal function in selective autophagy as its maintenance of the binding ability with optineurin through GST pull-down assay. However, further analysis such as autophagy flux assays should be performed so as to unequivocally identify the full function of TBK1 p.Ile334Thr in autophagy. Although aberrant autophagy is considered as a main cause of patients with TBK1 variants predisposed to FTD-ALS spectrum, evidence of neuroinflammation in TBK1 mutations also displayed its significance. Impaired migration of T cells was observed in TBK1 knockout mice, suggesting a decreased T-cell regulation which led to less stabilization of glial cell and proinflammatory cytokines (Komine & Yamanaka, 2015) . On the other hand, multiform effects of type I IFNs and cytokines have been demonstrated in neuron survival, suggesting IFN impairment in TBK1 mutations may also lead to the pathogenesis of FTD-ALS spectrum. In addition, possible relationship between IFN pathways and autophagy in disease has been considered (Watson et al., 2015) , implying that optineurin-TBK1 complexes may regulate IRF3-IFN responses. Whether such IFN impairment might also contribute to FTD pathogenesis is a possibility that remains unexplored.
There exist some limitations in this study. First, limited by the number of patients, we only detected one patient with p.Ile334Thr of TBK1. Although we detect that the mutation is likely pathogenic and can partially disturb neuroinflammatory pathway without interfering with the autophagy function of TBK1, additional patients with this mutation need to be identified with functional work. On the other hand, the decreased level of IFN-β signaling of this mutation indicated that besides the disturbance of neuroinflammatory pathway, there may still be some unknown pathogenic mechanism under this mutation that we have not yet discovered.
| CONCLUSION
In this article, we reported a TBK1 mutation of p.Ile334Thr in a Chinese bvFTD patient and classified it as likely pathogenic. Clinical evaluation confirmed the diagnosis of bvFTD, and functional analysis of the mutation demonstrated partially dysfunction of protein expression and activity of TBK1. Whether dysfunction of neuroinflammatory pathways reveals a general feature of p.Ile334Thr mutation of TBK1 remains to be explored. Further study will focus on the pathogenesis of this mutation on FTD and its relationship with ALS.
